Cornerstone Therapeutics, Inc. (CRTX) Misses Q3 EPS by 1c, Sales Fall Below Expectations
Tweet
Share
E-mailGet Alerts CRTX Hot Sheet
Price: $1.95 --0%
Financial Fact:
Research and development: 594K
Today's EPS Names:
MSGM, SMID, VISL, More
Financial Fact:
Research and development: 594K
Today's EPS Names:
MSGM, SMID, VISL, More
Join SI Premium – FREE
Cornerstone Therapeutics, Inc. (NASDAQ: CRTX) reported Q3 non-GAAP EPS of $0.13, $0.01 worse than the analyst estimate of $0.14. Revenue for the quarter came in at $25.18 million versus the consensus estimate of $28.39 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Freightos Limited (CRGO) Tops Q2 EPS by 3c ; Offers Guidance
- Femasys Inc. (FEMY) Misses Q2 EPS by 20c
- Brainstorm Cell Therapeutics (BCLI) Misses Q2 EPS by 6c
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
